1
|
Nayak V, Patra S, Rout S, Jena AB, Sharma R, Pattanaik KP, Singh J, Pandey SS, Singh RP, Majhi S, Singh KR, Kerry RG. Regulation of neuroinflammation in Alzheimer's disease via nanoparticle-loaded phytocompounds with anti-inflammatory and autophagy-inducing properties. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2024; 122:155150. [PMID: 37944239 DOI: 10.1016/j.phymed.2023.155150] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 09/23/2023] [Accepted: 10/14/2023] [Indexed: 11/12/2023]
Abstract
BACKGROUND Alzheimer's disease (AD) is characterized by neuroinflammation linked to amyloid β (Aβ) aggregation and phosphorylated tau (τ) protein in neurofibrillary tangles (NFTs). Key elements in Aβ production and NFT assembly, like γ-secretase and p38 mitogen-activated protein kinase (p38MAPK), contribute to neuroinflammation. In addition, impaired proteosomal and autophagic pathways increase Aβ and τ aggregation, leading to neuronal damage. Conventional neuroinflammation drugs have limitations due to unidirectional therapeutic approaches and challenges in crossing the Blood-Brain Barrier (BBB). Clinical trials for non-steroidal anti-inflammatory drugs (NSAIDs) and other therapeutics remain uncertain. Novel strategies addressing the complex pathogenesis and BBB translocation are needed to effectively tackle AD-related neuroinflammation. PURPOSE The current scenario demands for a much-sophisticated theranostic measures which could be achieved via customized engineering and designing of novel nanotherapeutics. As, these therapeutics functions as a double edge sword, having the efficiency of unambiguous targeting, multiple drug delivery and ability to cross BBB proficiently. METHODS Inclusion criteria involve selecting recent, English-language studies from the past decade (2013-2023) that explore the regulation of neuroinflammation in neuroinflammation, Alzheimer's disease, amyloid β, tau protein, nanoparticles, autophagy, and phytocompounds. Various study types, including clinical trials, experiments, and reviews, were considered. Exclusion criteria comprised non-relevant publication types, studies unrelated to Alzheimer's disease or phytocompounds, those with methodological flaws, duplicates, and studies with inaccessible data. RESULTS In this study, polymeric nanoparticles loaded with specific phytocompounds and coated with an antibody targeting the transferrin receptor (anti-TfR) present on BBB. Thereafter, the engineered nanoparticles with the ability to efficiently traverse the BBB and interact with target molecules within the brain, could induce autophagy, a cellular process crucial for neuronal health, and exhibit potent anti-inflammatory effects. Henceforth, the proposed combination of desired phytocompounds, polymeric nanoparticles, and anti-TfR coating presents a promising approach for targeted drug delivery to the brain, with potential implications in neuroinflammatory conditions such as Alzheimer's disease.
Collapse
Affiliation(s)
- Vinayak Nayak
- ICAR- National Institute on Foot and Mouth Disease-International Centre for Foot and Mouth Disease, Arugul, Bhubaneswar, Odisha (752050), India
| | - Sushmita Patra
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, Maharashtra (410210), India
| | - Shrushti Rout
- Department of Biotechnology, Utkal University, Vani Vihar, Bhubaneswar, Odisha (751004), India
| | - Atala Bihari Jena
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (02115), United States of America
| | - Rohit Sharma
- Department of Rasa Shastra and Bhaishajya Kalpana, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh (221005), India
| | - Kali Prasad Pattanaik
- School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar 751024, India
| | - Jay Singh
- Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh (221005), India
| | - Shyam S Pandey
- Graduate School of Life Science and Systems Engineering, Kyushu Institute of Technology, 2-4 Hibikino, Wakamatsu, Kitakyushu (8080196), Japan
| | - Ravindra Pratap Singh
- Department of Biotechnology, Faculty of Science, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh 484887, India
| | - Sanatan Majhi
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (02115), United States of America
| | - Kshitij Rb Singh
- Graduate School of Life Science and Systems Engineering, Kyushu Institute of Technology, 2-4 Hibikino, Wakamatsu, Kitakyushu (8080196), Japan.
| | - Rout George Kerry
- Department of Biotechnology, Utkal University, Vani Vihar, Bhubaneswar, Odisha (751004), India.
| |
Collapse
|
2
|
Michaels TCT, Dear AJ, Cohen SIA, Vendruscolo M, Knowles TPJ. Kinetic profiling of therapeutic strategies for inhibiting the formation of amyloid oligomers. J Chem Phys 2022; 156:164904. [PMID: 35490011 DOI: 10.1063/5.0077609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Protein self-assembly into amyloid fibrils underlies several neurodegenerative conditions, including Alzheimer's and Parkinson's diseases. It has become apparent that the small oligomers formed during this process constitute neurotoxic molecular species associated with amyloid aggregation. Targeting the formation of oligomers represents, therefore, a possible therapeutic avenue to combat these diseases. However, it remains challenging to establish which microscopic steps should be targeted to suppress most effectively the generation of oligomeric aggregates. Recently, we have developed a kinetic model of oligomer dynamics during amyloid aggregation. Here, we use this approach to derive explicit scaling relationships that reveal how key features of the time evolution of oligomers, including oligomer peak concentration and lifetime, are controlled by the different rate parameters. We discuss the therapeutic implications of our framework by predicting changes in oligomer concentrations when the rates of the individual microscopic events are varied. Our results identify the kinetic parameters that control most effectively the generation of oligomers, thus opening a new path for the systematic rational design of therapeutic strategies against amyloid-related diseases.
Collapse
Affiliation(s)
- Thomas C T Michaels
- Department of Physics and Astronomy, Institute for the Physics of Living Systems, University College London, London, United Kingdom
| | - Alexander J Dear
- Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA
| | - Samuel I A Cohen
- Department of Physics and Astronomy, Institute for the Physics of Living Systems, University College London, London, United Kingdom
| | - Michele Vendruscolo
- Yusuf Hamied Department of Chemistry, Centre for Misfolding Diseases, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - Tuomas P J Knowles
- Yusuf Hamied Department of Chemistry, Centre for Misfolding Diseases, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| |
Collapse
|
3
|
Role of Receptors in Relation to Plaques and Tangles in Alzheimer's Disease Pathology. Int J Mol Sci 2021; 22:ijms222312987. [PMID: 34884789 PMCID: PMC8657621 DOI: 10.3390/ijms222312987] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2021] [Revised: 11/26/2021] [Accepted: 11/28/2021] [Indexed: 12/23/2022] Open
Abstract
Despite the identification of Aβ plaques and NFTs as biomarkers for Alzheimer’s disease (AD) pathology, therapeutic interventions remain elusive, with neither an absolute prophylactic nor a curative medication available to impede the progression of AD presently available. Current approaches focus on symptomatic treatments to maintain AD patients’ mental stability and behavioral symptoms by decreasing neuronal degeneration; however, the complexity of AD pathology requires a wide range of therapeutic approaches for both preventive and curative treatments. In this regard, this review summarizes the role of receptors as a potential target for treating AD and focuses on the path of major receptors which are responsible for AD progression. This review gives an overall idea centering on major receptors, their agonist and antagonist and future prospects of viral mimicry in AD pathology. This article aims to provide researchers and developers a comprehensive idea about the different receptors involved in AD pathogenesis that may lead to finding a new therapeutic strategy to treat AD.
Collapse
|
4
|
Rishton GM, Look GC, Ni ZJ, Zhang J, Wang Y, Huang Y, Wu X, Izzo NJ, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Catalano SM. Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease. ACS Med Chem Lett 2021; 12:1389-1395. [PMID: 34531947 DOI: 10.1021/acsmedchemlett.1c00048] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Accepted: 08/03/2021] [Indexed: 02/08/2023] Open
Abstract
An unbiased phenotypic neuronal assay was developed to measure the synaptotoxic effects of soluble Aβ oligomers. A collection of CNS druglike small molecules prepared by conditioned extraction was screened. Compounds that prevented and reversed synaptotoxic effects of Aβ oligomers in neurons were discovered to bind to the sigma-2 receptor complex. Select development compounds displaced receptor-bound Aβ oligomers, rescued synapses, and restored cognitive function in transgenic hAPP Swe/Ldn mice. Our first-in-class orally administered small molecule investigational drug 7 (CT1812) has been advanced to Phase II clinical studies for Alzheimer's disease.
Collapse
Affiliation(s)
- Gilbert M. Rishton
- Cognition Therapeutics, 2403 Sidney Street, Suite 261, Pittsburgh, Pennsylvania 15203, United States
| | - Gary C. Look
- Cognition Therapeutics, 2403 Sidney Street, Suite 261, Pittsburgh, Pennsylvania 15203, United States
| | - Zhi-Jie Ni
- Acme Bioscience, Inc., 3941 East Bayshore Road, Palo Alto, California 94303, United States
| | - Jason Zhang
- Acme Bioscience, Inc., 3941 East Bayshore Road, Palo Alto, California 94303, United States
| | - Yingcai Wang
- Acme Bioscience, Inc., 3941 East Bayshore Road, Palo Alto, California 94303, United States
| | - Yaodong Huang
- Acme Bioscience, Inc., 3941 East Bayshore Road, Palo Alto, California 94303, United States
| | - Xiaodong Wu
- Acme Bioscience, Inc., 3941 East Bayshore Road, Palo Alto, California 94303, United States
| | - Nicholas J. Izzo
- Cognition Therapeutics, 2403 Sidney Street, Suite 261, Pittsburgh, Pennsylvania 15203, United States
| | - Kelsie M LaBarbera
- Cognition Therapeutics, 2403 Sidney Street, Suite 261, Pittsburgh, Pennsylvania 15203, United States
| | - Colleen S. Limegrover
- Cognition Therapeutics, 2403 Sidney Street, Suite 261, Pittsburgh, Pennsylvania 15203, United States
| | - Courtney Rehak
- Cognition Therapeutics, 2403 Sidney Street, Suite 261, Pittsburgh, Pennsylvania 15203, United States
| | - Raymond Yurko
- Cognition Therapeutics, 2403 Sidney Street, Suite 261, Pittsburgh, Pennsylvania 15203, United States
| | - Susan M. Catalano
- Cognition Therapeutics, 2403 Sidney Street, Suite 261, Pittsburgh, Pennsylvania 15203, United States
| |
Collapse
|
5
|
Emerging Roles of Inhibitor of Differentiation-1 in Alzheimer's Disease: Cell Cycle Reentry and Beyond. Cells 2020; 9:cells9071746. [PMID: 32708313 PMCID: PMC7409121 DOI: 10.3390/cells9071746] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 07/09/2020] [Accepted: 07/18/2020] [Indexed: 12/22/2022] Open
Abstract
Inhibitor of DNA-binding/differentiation (Id) proteins, a family of helix-loop-helix (HLH) proteins that includes four members of Id1 to Id4 in mammalian cells, are critical for regulating cell growth, differentiation, senescence, cell cycle progression, and increasing angiogenesis and vasculogenesis, as well as accelerating the ability of cell migration. Alzheimer’s disease (AD), the most common neurodegenerative disease in the adult population, manifests the signs of cognitive decline, behavioral changes, and functional impairment. The underlying mechanisms for AD are not well-clarified yet, but the aggregation of amyloid-beta peptides (Aβs), the major components in the senile plaques observed in AD brains, contributes significantly to the disease progression. Emerging evidence reveals that aberrant cell cycle reentry may play a central role in Aβ-induced neuronal demise. Recently, we have shown that several signaling mediators, including Id1, hypoxia-inducible factor-1 (HIF-1), cyclin-dependent kinases-5 (CDK5), and sonic hedgehog (Shh), may contribute to Aβ-induced cell cycle reentry in postmitotic neurons; furthermore, Id1 and CDK5/p25 mutually antagonize the expression/activity of each other. Therefore, Id proteins may potentially have clinical applications in AD. In this review article, we introduce the underlying mechanisms for cell cycle dysregulation in AD and present some examples, including our own studies, to show different aspects of Id1 in terms of cell cycle reentry and other signaling that may be crucial to alter the neuronal fates in this devastating neurodegenerative disease. A thorough understanding of the underlying mechanisms may provide a rationale to make an earlier intervention before the occurrence of cell cycle reentry and subsequent apoptosis in the fully differentiated neurons during the progression of AD or other neurodegenerative diseases.
Collapse
|
6
|
Michaels TCT, Šarić A, Curk S, Bernfur K, Arosio P, Meisl G, Dear AJ, Cohen SIA, Dobson CM, Vendruscolo M, Linse S, Knowles TPJ. Dynamics of oligomer populations formed during the aggregation of Alzheimer's Aβ42 peptide. Nat Chem 2020; 12:445-451. [PMID: 32284577 DOI: 10.1038/s41557-020-0452-1] [Citation(s) in RCA: 179] [Impact Index Per Article: 44.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 03/02/2020] [Indexed: 01/10/2023]
Abstract
Oligomeric species populated during the aggregation of the Aβ42 peptide have been identified as potent cytotoxins linked to Alzheimer's disease, but the fundamental molecular pathways that control their dynamics have yet to be elucidated. By developing a general approach that combines theory, experiment and simulation, we reveal, in molecular detail, the mechanisms of Aβ42 oligomer dynamics during amyloid fibril formation. Even though all mature amyloid fibrils must originate as oligomers, we found that most Aβ42 oligomers dissociate into their monomeric precursors without forming new fibrils. Only a minority of oligomers converts into fibrillar structures. Moreover, the heterogeneous ensemble of oligomeric species interconverts on timescales comparable to those of aggregation. Our results identify fundamentally new steps that could be targeted by therapeutic interventions designed to combat protein misfolding diseases.
Collapse
Affiliation(s)
- Thomas C T Michaels
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK.,Paulson School of Engineering and Applied Science, Harvard University, Cambridge, MA, USA
| | - Andela Šarić
- Department of Physics and Astronomy, Institute for the Physics of Living Systems, University College London, London, UK.,MRC Laboratory for Molecular Cell Biology, University College London, London, UK
| | - Samo Curk
- Department of Physics and Astronomy, Institute for the Physics of Living Systems, University College London, London, UK.,MRC Laboratory for Molecular Cell Biology, University College London, London, UK.,Faculty of Natural Sciences and Mathematics, University of Maribor, Maribor, Slovenia
| | - Katja Bernfur
- Department of Chemistry, Division for Biochemistry and Structural Biology, Lund University, Lund, Sweden
| | - Paolo Arosio
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
| | - Georg Meisl
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK
| | - Alexander J Dear
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK.,Paulson School of Engineering and Applied Science, Harvard University, Cambridge, MA, USA
| | - Samuel I A Cohen
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK
| | - Christopher M Dobson
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK
| | - Michele Vendruscolo
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK.
| | - Sara Linse
- Department of Chemistry, Division for Biochemistry and Structural Biology, Lund University, Lund, Sweden.
| | - Tuomas P J Knowles
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK. .,Cavendish Laboratory, University of Cambridge, Cambridge, UK.
| |
Collapse
|
7
|
Obrenovich M, Tabrez S, Siddiqui B, McCloskey B, Perry G. The Microbiota-Gut-Brain Axis-Heart Shunt Part II: Prosaic Foods and the Brain-Heart Connection in Alzheimer Disease. Microorganisms 2020; 8:E493. [PMID: 32244373 PMCID: PMC7232206 DOI: 10.3390/microorganisms8040493] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Revised: 03/19/2020] [Accepted: 03/26/2020] [Indexed: 02/07/2023] Open
Abstract
There is a strong cerebrovascular component to brain aging, Alzheimer disease, and vascular dementia. Foods, common drugs, and the polyphenolic compounds contained in wine modulate health both directly and through the gut microbiota. This observation and novel findings centered on nutrition, biochemistry, and metabolism, as well as the newer insights we gain into the microbiota-gut-brain axis, now lead us to propose a shunt to this classic triad, which involves the heart and cerebrovascular systems. The French paradox and prosaic foods, as they relate to the microbiota-gut-brain axis and neurodegenerative diseases, are discussed in this manuscript, which is the second part of a two-part series of concept papers addressing the notion that the microbiota and host liver metabolism all play roles in brain and heart health.
Collapse
Affiliation(s)
- Mark Obrenovich
- Research Service, Louis Stokes Cleveland, Department of Veteran’s Affairs Medical Center, Cleveland, OH 44106, USA
- Department of Chemistry, Case Western Reserve University, Cleveland, OH 44106, USA
- The Gilgamesh Foundation for Medical Science and Research, Cleveland, OH 44116, USA;
- Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43606, USA
- Departments of Chemistry and Biological and Environmental Sciences, Cleveland State University, Cleveland, OH 44115, USA
| | - Shams Tabrez
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia;
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Bushra Siddiqui
- North East Ohio College of Medicine, Rootstown, OH 44272, USA;
| | - Benjamin McCloskey
- The Gilgamesh Foundation for Medical Science and Research, Cleveland, OH 44116, USA;
| | - George Perry
- Department of Biology, University of Texas at San Antonio, San Antonio, TX 78249, USA;
| |
Collapse
|
8
|
The Interaction Between Contactin and Amyloid Precursor Protein and Its Role in Alzheimer’s Disease. Neuroscience 2020; 424:184-202. [DOI: 10.1016/j.neuroscience.2019.10.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 10/01/2019] [Accepted: 10/03/2019] [Indexed: 01/06/2023]
|
9
|
Feng L, Watanabe H, Molino P, Wallace GG, Phung SL, Uchihashi T, Higgins MJ. Dynamics of Inter-Molecular Interactions Between Single Aβ42 Oligomeric and Aggregate Species by High-Speed Atomic Force Microscopy. J Mol Biol 2019; 431:2687-2699. [DOI: 10.1016/j.jmb.2019.04.044] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Revised: 04/12/2019] [Accepted: 04/29/2019] [Indexed: 01/29/2023]
|
10
|
Weber C, Michaels T, Mahadevan L. Spatial control of irreversible protein aggregation. eLife 2019; 8:e42315. [PMID: 31084715 PMCID: PMC6516824 DOI: 10.7554/elife.42315] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2018] [Accepted: 04/01/2019] [Indexed: 12/19/2022] Open
Abstract
Liquid cellular compartments form in the cyto- or nucleoplasm and can regulate aberrant protein aggregation. Yet, the mechanisms by which these compartments affect protein aggregation remain unknown. Here, we combine kinetic theory of protein aggregation and liquid-liquid phase separation to study the spatial control of irreversible protein aggregation in the presence of liquid compartments. We find that even for weak interactions aggregates strongly partition into the liquid compartment. Aggregate partitioning is caused by a positive feedback mechanism of aggregate nucleation and growth driven by a flux maintaining the phase equilibrium between the compartment and its surrounding. Our model establishes a link between specific aggregating systems and the physical conditions maximizing aggregate partitioning into the compartment. The underlying mechanism of aggregate partitioning could be used to confine cytotoxic protein aggregates inside droplet-like compartments but may also represent a common mechanism to spatially control irreversible chemical reactions in general.
Collapse
Affiliation(s)
- Christoph Weber
- School of Engineering and Applied SciencesHarvard UniversityCambridgeUnited States
| | - Thomas Michaels
- School of Engineering and Applied SciencesHarvard UniversityCambridgeUnited States
| | - L Mahadevan
- Department of PhysicsHarvard UniversityCambridgeUnited States
- Department of Organismic and Evolutionary BiologyHarvard UniversityCambridgeUnited States
- Kavli Institute for NanoBio Science and TechnologyHarvard UniversityCambridgeUnited States
| |
Collapse
|
11
|
Abstract
The recent Research Framework proposed by the US National Institute on Aging and the Alzheimer's Association (NIA-AA) recommends that Alzheimer's disease be defined by its specific biology rather than by non-specific neurodegenerative and syndromal features. By affirming markers of abnormal Aβ and tau proteins as the essential pathobiological signature of Alzheimer's disease, the Framework tacitly reinforces the amyloid (Aβ) cascade as the leading theory of Alzheimer pathogenesis. In light of recent evidence that the cascade is driven by the misfolding and templated aggregation of Aβ and tau, we believe that an empirically grounded Standard Model of Alzheimer's pathogenesis is within reach. A Standard Model can clarify and consolidate existing information, contextualize risk factors and the complex disease phenotype, identify testable hypotheses for future research, and pave the most direct path to effective prevention and treatment.
Collapse
Affiliation(s)
- Lary C Walker
- a Department of Neurology and Yerkes National Primate Research Center , Emory University , Atlanta , GA , USA
| | - David G Lynn
- b Departments of Biology and Chemistry , Emory University , Atlanta , GA , USA
| | - Yury O Chernoff
- c School of Biological Sciences , Georgia Institute of Technology , Atlanta , GA , USA.,d Laboratory of Amyloid Biology and Institute of Translational Biomedicine , St. Petersburg State University , St. Petersburg , Russia
| |
Collapse
|
12
|
Dunys J, Valverde A, Checler F. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease? J Biol Chem 2018; 293:15419-15428. [PMID: 30143530 DOI: 10.1074/jbc.r118.003999] [Citation(s) in RCA: 73] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The histopathology of Alzheimer's disease (AD) is characterized by neuronal loss, neurofibrillary tangles, and senile plaque formation. The latter results from an exacerbated production (familial AD cases) or altered degradation (sporadic cases) of 40/42-amino acid-long β-amyloid peptides (Aβ peptides) that are produced by sequential cleavages of Aβ precursor protein (βAPP) by β- and γ-secretases. The amyloid cascade hypothesis proposes a key role for the full-length Aβ42 and the Aβ40/42 ratio in AD etiology, in which soluble Aβ oligomers lead to neurotoxicity, tau hyperphosphorylation, aggregation, and, ultimately, cognitive defects. However, following this postulate, during the last decade, several clinical approaches aimed at decreasing full-length Aβ42 production or neutralizing it by immunotherapy have failed to reduce or even stabilize AD-related decline. Thus, the Aβ peptide (Aβ40/42)-centric hypothesis is probably a simplified view of a much more complex situation involving a multiplicity of APP fragments and Aβ catabolites. Indeed, biochemical analyses of AD brain deposits and fluids have unraveled an Aβ peptidome consisting of additional Aβ-related species. Such Aβ catabolites could be due to either primary enzymatic cleavages of βAPP or secondary processing of Aβ itself by exopeptidases. Here, we review the diversity of N- and C-terminally truncated Aβ peptides and their biosynthesis and outline their potential function/toxicity. We also highlight their potential as new pharmaceutical targets and biomarkers.
Collapse
Affiliation(s)
- Julie Dunys
- From the Université Côte d'Azur, INSERM, CNRS, IPMC, Team labeled "Laboratory of Excellence (LABEX) Distalz," 660 Route des Lucioles, Sophia-Antipolis, 06560 Valbonne, France
| | - Audrey Valverde
- From the Université Côte d'Azur, INSERM, CNRS, IPMC, Team labeled "Laboratory of Excellence (LABEX) Distalz," 660 Route des Lucioles, Sophia-Antipolis, 06560 Valbonne, France
| | - Frédéric Checler
- From the Université Côte d'Azur, INSERM, CNRS, IPMC, Team labeled "Laboratory of Excellence (LABEX) Distalz," 660 Route des Lucioles, Sophia-Antipolis, 06560 Valbonne, France
| |
Collapse
|
13
|
Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, Götz J. Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies. Nat Rev Neurol 2017; 14:22-39. [DOI: 10.1038/nrneurol.2017.162] [Citation(s) in RCA: 235] [Impact Index Per Article: 33.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
14
|
Parsons CG, Rammes G. Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease. Expert Opin Investig Drugs 2017; 26:579-592. [DOI: 10.1080/13543784.2017.1313832] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Chris G. Parsons
- Non-Clinical Science, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany
| | - Gerhard Rammes
- Klinikum rechts der Isar der Technischen Universitat Munchen – Department of Anesthesiology, Munchen, Germany
| |
Collapse
|
15
|
Michaels TCT, Liu LX, Meisl G, Knowles TPJ. Physical principles of filamentous protein self-assembly kinetics. JOURNAL OF PHYSICS. CONDENSED MATTER : AN INSTITUTE OF PHYSICS JOURNAL 2017; 29:153002. [PMID: 28170349 DOI: 10.1088/1361-648x/aa5f10] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The polymerization of proteins and peptides into filamentous supramolecular structures is an elementary form of self-organization of key importance to the functioning biological systems, as in the case of actin biofilaments that compose the cellular cytoskeleton. Aberrant filamentous protein self-assembly, however, is associated with undesired effects and severe clinical disorders, such as Alzheimer's and Parkinson's diseases, which, at the molecular level, are associated with the formation of certain forms of filamentous protein aggregates known as amyloids. Moreover, due to their unique physicochemical properties, protein filaments are finding extensive applications as biomaterials for nanotechnology. With all these different factors at play, the field of filamentous protein self-assembly has experienced tremendous activity in recent years. A key question in this area has been to elucidate the microscopic mechanisms through which filamentous aggregates emerge from dispersed proteins with the goal of uncovering the underlying physical principles. With the latest developments in the mathematical modeling of protein aggregation kinetics as well as the improvement of the available experimental techniques it is now possible to tackle many of these complex systems and carry out detailed analyses of the underlying microscopic steps involved in protein filament formation. In this paper, we review some classical and modern kinetic theories of protein filament formation, highlighting their use as a general strategy for quantifying the molecular-level mechanisms and transition states involved in these processes.
Collapse
Affiliation(s)
- Thomas C T Michaels
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, United Kingdom. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, United States of America
| | | | | | | |
Collapse
|
16
|
Michaels TC, Dear AJ, Knowles TP. Scaling and dimensionality in the chemical kinetics of protein filament formation. INT REV PHYS CHEM 2016. [DOI: 10.1080/0144235x.2016.1239335] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Assessing the Effects of Acute Amyloid β Oligomer Exposure in the Rat. Int J Mol Sci 2016; 17:ijms17091390. [PMID: 27563885 PMCID: PMC5037670 DOI: 10.3390/ijms17091390] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2016] [Revised: 08/16/2016] [Accepted: 08/18/2016] [Indexed: 11/28/2022] Open
Abstract
Alzheimer’s disease (AD) is the most common form of dementia, yet there are no therapeutic treatments that can either cure or delay its onset. Currently, the pathogenesis of AD is still uncertain, especially with respect to how the disease develops from a normal healthy brain. Amyloid β oligomers (AβO) are highly neurotoxic proteins and are considered potential initiators to the pathogenesis of AD. Rat brains were exposed to AβO via bilateral intracerebroventricular injections. Rats were then euthanized at either 1, 3, 7 or 21-days post surgery. Rat behavioural testing was performed using the Morris water maze and open field tests. Post-mortem brain tissue was immunolabelled for Aβ, microglia, and cholinergic neurons. Rats exposed to AβO showed deficits in spatial learning and anxiety-like behaviour. Acute positive staining for Aβ was only observed in the corpus callosum surrounding the lateral ventricles. AβO exposed rat brains also showed a delayed increase in activated microglia within the corpus callosum and a decreased number of cholinergic neurons within the basal forebrain. Acute exposure to AβO resulted in mild learning and memory impairments with co-concomitant white matter pathology within the corpus callosum and cholinergic cell loss within the basal forebrain. Results suggest that acute exposure to AβO in the rat may be a useful tool in assessing the early phases for the pathogenesis of AD.
Collapse
|
18
|
Michaels TCT, Lazell HW, Arosio P, Knowles TPJ. Dynamics of protein aggregation and oligomer formation governed by secondary nucleation. J Chem Phys 2016; 143:054901. [PMID: 26254664 DOI: 10.1063/1.4927655] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The formation of aggregates in many protein systems can be significantly accelerated by secondary nucleation, a process where existing assemblies catalyse the nucleation of new species. In particular, secondary nucleation has emerged as a central process controlling the proliferation of many filamentous protein structures, including molecular species related to diseases such as sickle cell anemia and a range of neurodegenerative conditions. Increasing evidence suggests that the physical size of protein filaments plays a key role in determining their potential for deleterious interactions with living cells, with smaller aggregates of misfolded proteins, oligomers, being particularly toxic. It is thus crucial to progress towards an understanding of the factors that control the sizes of protein aggregates. However, the influence of secondary nucleation on the time evolution of aggregate size distributions has been challenging to quantify. This difficulty originates in large part from the fact that secondary nucleation couples the dynamics of species distant in size space. Here, we approach this problem by presenting an analytical treatment of the master equation describing the growth kinetics of linear protein structures proliferating through secondary nucleation and provide closed-form expressions for the temporal evolution of the resulting aggregate size distribution. We show how the availability of analytical solutions for the full filament distribution allows us to identify the key physical parameters that control the sizes of growing protein filaments. Furthermore, we use these results to probe the dynamics of the populations of small oligomeric species as they are formed through secondary nucleation and discuss the implications of our work for understanding the factors that promote or curtail the production of these species with a potentially high deleterious biological activity.
Collapse
Affiliation(s)
- Thomas C T Michaels
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - Hamish W Lazell
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - Paolo Arosio
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - Tuomas P J Knowles
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| |
Collapse
|
19
|
Rosen RF, Tomidokoro Y, Farberg AS, Dooyema J, Ciliax B, Preuss TM, Neubert TA, Ghiso JA, LeVine H, Walker LC. Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease. Neurobiol Aging 2016; 44:185-196. [PMID: 27318146 DOI: 10.1016/j.neurobiolaging.2016.04.019] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Revised: 04/22/2016] [Accepted: 04/23/2016] [Indexed: 10/21/2022]
Abstract
The misfolding and accumulation of the protein fragment β-amyloid (Aβ) is an early and essential event in the pathogenesis of Alzheimer's disease (AD). Despite close biological similarities among primates, humans appear to be uniquely susceptible to the profound neurodegeneration and dementia that characterize AD, even though nonhuman primates deposit copious Aβ in senile plaques and cerebral amyloid-β angiopathy as they grow old. Because the amino acid sequence of Aβ is identical in all primates studied to date, we asked whether differences in the properties of aggregated Aβ might underlie the vulnerability of humans and the resistance of other primates to AD. In a comparison of aged squirrel monkeys (Saimiri sciureus) and humans with AD, immunochemical and mass spectrometric analyses indicate that the populations of Aβ fragments are largely similar in the 2 species. In addition, Aβ-rich brain extracts from the brains of aged squirrel monkeys and AD patients similarly seed the deposition of Aβ in a transgenic mouse model. However, the epitope exposure of aggregated Aβ differs in sodium dodecyl sulfate-stable oligomeric Aβ from the 2 species. In addition, the high-affinity binding of (3)H Pittsburgh Compound B to Aβ is significantly diminished in tissue extracts from squirrel monkeys compared with AD patients. These findings support the hypothesis that differences in the pathobiology of aggregated Aβ among primates are linked to post-translational attributes of the misfolded protein, such as molecular conformation and/or the involvement of species-specific cofactors.
Collapse
Affiliation(s)
- Rebecca F Rosen
- Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
| | | | - Aaron S Farberg
- Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA
| | - Jeromy Dooyema
- Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA
| | - Brian Ciliax
- Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
| | - Todd M Preuss
- Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Thomas A Neubert
- Department of Biochemistry and Molecular Pharmacology, Kimmel Center for Biology and Medicine at the Skirball Institute, NYU School of Medicine, New York, NY, USA
| | - Jorge A Ghiso
- Department of Pathology, NYU School of Medicine, New York, NY, USA; Department of Psychiatry, NYU School of Medicine, New York, NY, USA
| | - Harry LeVine
- Department of Molecular & Cellular Biochemistry, Center on Aging, Center for Structural Biology, University of Kentucky, Lexington, KY, USA
| | - Lary C Walker
- Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
| |
Collapse
|
20
|
LeVine H, Walker LC. What amyloid ligands can tell us about molecular polymorphism and disease. Neurobiol Aging 2016; 42:205-12. [PMID: 27143437 DOI: 10.1016/j.neurobiolaging.2016.03.019] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2016] [Revised: 03/15/2016] [Accepted: 03/16/2016] [Indexed: 12/19/2022]
Abstract
Brain-penetrant positron emission tomography imaging ligands selective for amyloid pathology in living subjects have sparked a revolution in presymptomatic biomarkers for Alzheimer's disease progression. As additional chemical structures were investigated, the heterogeneity of ligand-binding sites became apparent, as did discrepancies in binding of some ligands between human disease and animal models. These differences and their implications have received little attention. This review discusses the impact of different ligand-binding sites and misfolded protein conformational polymorphism on the interpretation of imaging data acquired with different ligands. Investigation of the differences in binding in animal models may identify pathologic processes informing improvements to these models for more faithful recapitulation of this uniquely human disease. The differential selectivity for binding of particular ligands to different conformational states could potentially be harnessed to better define disease progression and improve the prediction of clinical outcomes.
Collapse
Affiliation(s)
- Harry LeVine
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, USA; Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA; Department of Molecular and Cellular Biochemistry, Center for Structural Biology, University of Kentucky, Lexington, KY, USA.
| | - Lary C Walker
- Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Neurology, Emory University, Atlanta, GA, USA
| |
Collapse
|
21
|
Abstract
Alzheimer disease (AD) is a fatal progressive disease and the most common form of dementia without effective treatments. Previous studies support that the disruption of endoplasmic reticulum Ca through overactivation of ryanodine receptors plays an important role in the pathogenesis of AD. Normalization of intracellular Ca homeostasis could be an effective strategy for AD therapies. Dantrolene, an antagonist of ryanodine receptors and an FDA-approved drug for clinical treatment of malignant hyperthermia and muscle spasms, exhibits neuroprotective effects in multiple models of neurodegenerative disorders. Recent preclinical studies consistently support the therapeutic effects of dantrolene in various types of AD animal models and were summarized in the current review.
Collapse
|
22
|
Kumar R, Nordberg A, Darreh-Shori T. Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs. Brain 2015; 139:174-92. [PMID: 26525916 PMCID: PMC4949388 DOI: 10.1093/brain/awv318] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Accepted: 09/18/2015] [Indexed: 12/02/2022] Open
Abstract
Amyloid-β peptides, through highly sophisticated enzymatic machinery, are universally produced and released in an action potential synchronized manner into the interstitial fluids in the brain. Yet no native functions are attributed to amyloid-β. The amyloid-β hypothesis ascribes just neurotoxicity properties through build-up of soluble homomeric amyloid-β oligomers or fibrillar deposits. Apolipoprotein-ε4 (APOE4) allele is the only confirmed genetic risk factor of sporadic Alzheimer’s disease; once more it is unclear how it increases the risk of Alzheimer’s disease. Similarly, central cholinergic signalling is affected selectively and early in the Alzheimer’s disease brain, again why cholinergic neurons show this sensitivity is still unclear. However, the three main known Alzheimer’s disease risk factors, advancing age, female gender and APOE4, have been linked to a high apolipoprotein-E and accumulation of the acetylcholine degrading enzyme, butyrylcholinesterase in cerebrospinal fluids of patients. Furthermore, numerous reports indicate that amyloid-β interacts with butyrylcholinesterase and apolipoprotein-E. We have proposed that this interaction leads to formation of soluble ultrareactive acetylcholine-hydrolyzing complexes termed BAβACs, to adjust at demand both synaptic and extracellular acetylcholine signalling. This hypothesis predicted presence of acetylcholine-synthesizing enzyme, choline acetyltransferase in extracellular fluids to allow maintenance of equilibrium between breakdown and synthesis of acetylcholine through continuous
in situ
syntheses. A recent proof-of-concept study led to the discovery of this enzyme in the human extracellular fluids. We report here that apolipoprotein-E, in particular ε4 isoprotein acts as one of the strongest endogenous anti-amyloid-β fibrillization agents reported in the literature. At biological concentrations, apolipoprotein-E prevented amyloid-β fibrillization for at least 65 h. We show that amyloid-β interacts readily in an apolipoprotein-facilitated manner with butyrylcholinesterase, forming highly stable and soluble complexes, BAβACs, which can be separated in their native states by sucrose density gradient technique. Enzymological analyses further evinced that amyloid-β concentration dependently increased the acetylcholine-hydrolyzing capacity of cholinesterases.
In silico
biomolecular analysis further deciphered the allosteric amino acid fingerprint of the amyloid-β-cholinesterase molecular interaction in formation of BAβACs. In the case of butyrylcholinesterase, the results indicated that amyloid-β interacts with a putative activation site at the mouth of its catalytic tunnel, most likely leading to increased acetylcholine influx into the catalytic site, and thereby increasing the intrinsic catalytic rate of butyrylcholinesterase. In conclusion, at least one of the native physiological functions of amyloid-β is allosteric modulation of the intrinsic catalytic efficiency of cholinesterases, and thereby regulation of synaptic and extrasynaptic cholinergic signalling. High apolipoprotein-E may pathologically alter the biodynamics of this amyloid-β function.
Collapse
Affiliation(s)
- Rajnish Kumar
- 1 Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, NOVUM, 4th Floor, 141 86 Stockholm, Sweden
| | - Agneta Nordberg
- 1 Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, NOVUM, 4th Floor, 141 86 Stockholm, Sweden 2 Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm
| | - Taher Darreh-Shori
- 1 Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, NOVUM, 4th Floor, 141 86 Stockholm, Sweden
| |
Collapse
|
23
|
Dineen TA, Chen K, Cheng AC, Derakhchan K, Epstein O, Esmay J, Hickman D, Kreiman CE, Marx IE, Wahl RC, Wen PH, Weiss MM, Whittington DA, Wood S, Fremeau RT, White RD, Patel VF. Inhibitors of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1): Identification of (S)-7-(2-Fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (AMG-8718). J Med Chem 2014; 57:9811-31. [DOI: 10.1021/jm5012676] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Thomas A. Dineen
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Kui Chen
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Alan C. Cheng
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Katayoun Derakhchan
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Oleg Epstein
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Joel Esmay
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Dean Hickman
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Chuck E. Kreiman
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Isaac E. Marx
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Robert C. Wahl
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Paul H. Wen
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Matthew M. Weiss
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Douglas A. Whittington
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Stephen Wood
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Robert T. Fremeau
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Ryan D. White
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Vinod F. Patel
- Departments of Therapeutic
Discovery, ‡Neuroscience, §Molecular Structure and Characterization, ∥Pharmacokinetics
and Drug Metabolism, and ⊥Comparative Biology and Safety Sciences, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, and One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|
24
|
Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H, Catalano SM. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS One 2014; 9:e111898. [PMID: 25390368 PMCID: PMC4229098 DOI: 10.1371/journal.pone.0111898] [Citation(s) in RCA: 102] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Accepted: 10/02/2014] [Indexed: 01/09/2023] Open
Abstract
Synaptic dysfunction and loss caused by age-dependent accumulation of synaptotoxic beta amyloid (Abeta) 1-42 oligomers is proposed to underlie cognitive decline in Alzheimer's disease (AD). Alterations in membrane trafficking induced by Abeta oligomers mediates reduction in neuronal surface receptor expression that is the basis for inhibition of electrophysiological measures of synaptic plasticity and thus learning and memory. We have utilized phenotypic screens in mature, in vitro cultures of rat brain cells to identify small molecules which block or prevent the binding and effects of Abeta oligomers. Synthetic Abeta oligomers bind saturably to a single site on neuronal synapses and induce deficits in membrane trafficking in neuronal cultures with an EC50 that corresponds to its binding affinity. The therapeutic lead compounds we have found are pharmacological antagonists of Abeta oligomers, reducing the binding of Abeta oligomers to neurons in vitro, preventing spine loss in neurons and preventing and treating oligomer-induced deficits in membrane trafficking. These molecules are highly brain penetrant and prevent and restore cognitive deficits in mouse models of Alzheimer's disease. Counter-screening these compounds against a broad panel of potential CNS targets revealed they are highly potent and specific ligands of the sigma-2/PGRMC1 receptor. Brain concentrations of the compounds corresponding to greater than 80% receptor occupancy at the sigma-2/PGRMC1 receptor restore cognitive function in transgenic hAPP Swe/Ldn mice. These studies demonstrate that synthetic and human-derived Abeta oligomers act as pharmacologically-behaved ligands at neuronal receptors--i.e. they exhibit saturable binding to a target, they exert a functional effect related to their binding and their displacement by small molecule antagonists blocks their functional effect. The first-in-class small molecule receptor antagonists described here restore memory to normal in multiple AD models and sustain improvement long-term, representing a novel mechanism of action for disease-modifying Alzheimer's therapeutics.
Collapse
Affiliation(s)
- Nicholas J. Izzo
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
- * E-mail:
| | - Agnes Staniszewski
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America
| | - Lillian To
- Stanford University Medical School Behavioral and Functional Neuroscience Laboratory, Palo Alto, California, United States of America
| | - Mauro Fa
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America
| | - Andrew F. Teich
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America
| | - Faisal Saeed
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America
| | - Harrison Wostein
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Thomas Walko
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Anisha Vaswani
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Meghan Wardius
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Zanobia Syed
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Jessica Ravenscroft
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Kelsie Mozzoni
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Colleen Silky
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Courtney Rehak
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Raymond Yurko
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Patricia Finn
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Gary Look
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Gilbert Rishton
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Hank Safferstein
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Miles Miller
- Department of Pathology and Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America
| | - Conrad Johanson
- Department of Pathology and Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America
| | - Edward Stopa
- Department of Pathology and Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States of America
| | | | | | - Mehrdad Shamloo
- Stanford University Medical School Behavioral and Functional Neuroscience Laboratory, Palo Alto, California, United States of America
| | - Ottavio Arancio
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America
| | - Harry LeVine
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States of America
| | - Susan M. Catalano
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| |
Collapse
|
25
|
Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH, Craven R, Head E, LeVine H, Spires-Jones TL, Catalano SM. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One 2014; 9:e111899. [PMID: 25390692 PMCID: PMC4229119 DOI: 10.1371/journal.pone.0111899] [Citation(s) in RCA: 128] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2014] [Accepted: 10/02/2014] [Indexed: 12/18/2022] Open
Abstract
Amyloid beta (Abeta) 1-42 oligomers accumulate in brains of patients with Mild Cognitive Impairment (MCI) and disrupt synaptic plasticity processes that underlie memory formation. Synaptic binding of Abeta oligomers to several putative receptor proteins is reported to inhibit long-term potentiation, affect membrane trafficking and induce reversible spine loss in neurons, leading to impaired cognitive performance and ultimately to anterograde amnesia in the early stages of Alzheimer's disease (AD). We have identified a receptor not previously associated with AD that mediates the binding of Abeta oligomers to neurons, and describe novel therapeutic antagonists of this receptor capable of blocking Abeta toxic effects on synapses in vitro and cognitive deficits in vivo. Knockdown of sigma-2/PGRMC1 (progesterone receptor membrane component 1) protein expression in vitro using siRNA results in a highly correlated reduction in binding of exogenous Abeta oligomers to neurons of more than 90%. Expression of sigma-2/PGRMC1 is upregulated in vitro by treatment with Abeta oligomers, and is dysregulated in Alzheimer's disease patients' brain compared to age-matched, normal individuals. Specific, high affinity small molecule receptor antagonists and antibodies raised against specific regions on this receptor can displace synthetic Abeta oligomer binding to synaptic puncta in vitro and displace endogenous human AD patient oligomers from brain tissue sections in a dose-dependent manner. These receptor antagonists prevent and reverse the effects of Abeta oligomers on membrane trafficking and synapse loss in vitro and cognitive deficits in AD mouse models. These findings suggest sigma-2/PGRMC1 receptors mediate saturable oligomer binding to synaptic puncta on neurons and that brain penetrant, small molecules can displace endogenous and synthetic oligomers and improve cognitive deficits in AD models. We propose that sigma-2/PGRMC1 is a key mediator of the pathological effects of Abeta oligomers in AD and is a tractable target for small molecule disease-modifying therapeutics.
Collapse
Affiliation(s)
- Nicholas J. Izzo
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Jinbin Xu
- Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri, United States of America
| | - Chenbo Zeng
- Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri, United States of America
| | - Molly J. Kirk
- Departments of Neurology and Neuroscience, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
- Department of Neurology, Northeastern University, Boston, Massachusetts, United States of America
| | - Kelsie Mozzoni
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Colleen Silky
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Courtney Rehak
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Raymond Yurko
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Gary Look
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Gilbert Rishton
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Hank Safferstein
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| | - Carlos Cruchaga
- Department of Psychiatry, Washington University, St. Louis, Missouri, United States of America
| | - Alison Goate
- Department of Psychiatry, Washington University, St. Louis, Missouri, United States of America
| | - Michael A. Cahill
- School of Biomedical Sciences, Charles Sturt University, Wagga Wagga New South Wales, Australia
| | - Ottavio Arancio
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University New York, New York, United States of America
| | - Robert H. Mach
- Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri, United States of America
| | - Rolf Craven
- Department of Molecular and Biological Pharmacology, University of Kentucky, Lexington, Kentucky, United States of America
| | - Elizabeth Head
- Department of Molecular and Biological Pharmacology, University of Kentucky, Lexington, Kentucky, United States of America
| | - Harry LeVine
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States of America
| | - Tara L. Spires-Jones
- Departments of Neurology and Neuroscience, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
- The University of Edinburgh, Center for Cognitive and Neural Systems and Euan MacDonald Centre for Motorneurone Disease, Edinburgh, Scotland
| | - Susan M. Catalano
- Cognition Therapeutics Inc., Pittsburgh, Pennsylvania, United States of America
| |
Collapse
|
26
|
Sant'Anna R, Braga C, Varejão N, Pimenta KM, Graña-Montes R, Alves A, Cortines J, Cordeiro Y, Ventura S, Foguel D. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses. J Biol Chem 2014; 289:28324-37. [PMID: 25086037 PMCID: PMC4192486 DOI: 10.1074/jbc.m114.563981] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Protein aggregation into β-sheet-enriched amyloid fibrils is associated with an increasing number of human disorders. The adoption of such amyloid conformations seems to constitute a generic property of polypeptide chains. Therefore, during evolution, proteins have adopted negative design strategies to diminish their intrinsic propensity to aggregate, including enrichment of gatekeeper charged residues at the flanks of hydrophobic aggregation-prone segments. Wild type transthyretin (TTR) is responsible for senile systemic amyloidosis, and more than 100 mutations in the TTR gene are involved in familial amyloid polyneuropathy. The TTR 26–57 segment bears many of these aggressive amyloidogenic mutations as well as the binding site for heparin. We demonstrate here that Lys-35 acts as a gatekeeper residue in TTR, strongly decreasing its amyloidogenic potential. This protective effect is sequence-specific because Lys-48 does not affect TTR aggregation. Lys-35 is part of the TTR basic heparin-binding motif. This glycosaminoglycan blocks the protective effect of Lys-35, probably by neutralization of its side chain positive charge. A K35L mutation emulates this effect and results in the rapid self-assembly of the TTR 26–57 region into amyloid fibrils. This mutation does not affect the tetrameric protein stability, but it strongly increases its aggregation propensity. Overall, we illustrate how TTR is yet another amyloidogenic protein exploiting negative design to prevent its massive aggregation, and we show how blockage of conserved protective features by endogenous factors or mutations might result in increased disease susceptibility.
Collapse
Affiliation(s)
- Ricardo Sant'Anna
- From the Instituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Estrutural
| | - Carolina Braga
- From the Instituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Estrutural
| | - Nathalia Varejão
- From the Instituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Estrutural
| | - Karinne M Pimenta
- From the Instituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Estrutural
| | - Ricardo Graña-Montes
- the Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - Aline Alves
- From the Instituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Estrutural
| | - Juliana Cortines
- the Instituto de Microbiologia Professor Paulo de Goés, Universidade Federal do Rio de Janeiro, Rio de Janeiro CEP 21941-590, Brazil and
| | | | - Salvador Ventura
- the Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - Debora Foguel
- From the Instituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Estrutural,
| |
Collapse
|
27
|
Amtul Z, Whitehead SN, Keeley RJ, Bechberger J, Fisher AL, McDonald RJ, Naus CC, Munoz DG, Cechetto DF. Comorbid rat model of ischemia and β-amyloid toxicity: striatal and cortical degeneration. Brain Pathol 2014; 25:24-32. [PMID: 24725245 DOI: 10.1111/bpa.12149] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Accepted: 04/02/2014] [Indexed: 12/23/2022] Open
Abstract
Levels of cerebral amyloid, presumably β-amyloid (Abeta), toxicity and the incidence of cortical and subcortical ischemia increases with age. However, little is known about the severe pathological condition and dementia that occur as a result of the comorbid occurrence of this vascular risk factor and Abeta toxicity. Clinical studies have indicated that small ischemic lesions in the striatum are particularly important in generating dementia in combination with minor amyloid lesions. These cognitive deficits are highly likely to be caused by changes in the cortex. In this study, we examined the viability and morphological changes in microglial and neuronal cells, gap junction proteins (connexin43) and neuritic/axonal retraction (Fer Kinase) in the striatum and cerebral cortex using a comorbid rat model of striatal injections of endothelin-1 (ET1) and Abeta toxicity. The results demonstrated ventricular enlargement, striatal atrophy, substantial increases in β-amyloid, ramified microglia and increases in neuritic retraction in the combined models of stroke and Abeta toxicity. Changes in connexin43 occurred equally in both groups of Abeta-treated rats, with and without focal ischemia. Although previous behavioral tests demonstrated impairment in memory and learning, the visual discrimination radial maze task did not show significant difference, suggesting the cognitive impairment in these models is not related to damage to the dorsolateral striatum. These results suggest an insight into the relationship between cortical/striatal atrophy, pathology and functional impairment.
Collapse
Affiliation(s)
- Zareen Amtul
- CIHR Group on Vascular Cognitive Impairment, Department of Anatomy and Cell Biology, Western University, London, ON, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Huang D, Wang Z, Xia J, Zhang P, Kirkland B, Paravastu AK, Guan J. Microcontact printing of Alzheimer’s β-amyloid monomers and fibrils. Eur Polym J 2013. [DOI: 10.1016/j.eurpolymj.2013.06.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Lee WH, Loo CY, Bebawy M, Luk F, Mason RS, Rohanizadeh R. Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol 2013; 11:338-78. [PMID: 24381528 PMCID: PMC3744901 DOI: 10.2174/1570159x11311040002] [Citation(s) in RCA: 296] [Impact Index Per Article: 26.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2013] [Revised: 03/17/2013] [Accepted: 03/19/2013] [Indexed: 12/15/2022] Open
Abstract
Curcumin (diferuloylmethane), a polyphenol extracted from the plant Curcuma longa, is widely used in Southeast Asia, China and India in food preparation and for medicinal purposes. Since the second half of the last century, this traditional medicine has attracted the attention of scientists from multiple disciplines to elucidate its pharmacological properties. Of significant interest is curcumin's role to treat neurodegenerative diseases including Alzheimer's disease (AD), and Parkinson's disease (PD) and malignancy. These diseases all share an inflammatory basis, involving increased cellular reactive oxygen species (ROS) accumulation and oxidative damage to lipids, nucleic acids and proteins. The therapeutic benefits of curcumin for these neurodegenerative diseases appear multifactorial via regulation of transcription factors, cytokines and enzymes associated with (Nuclear factor kappa beta) NFκB activity. This review describes the historical use of curcumin in medicine, its chemistry, stability and biological activities, including curcumin's anti-cancer, anti-microbial, anti-oxidant, and anti-inflammatory properties. The review further discusses the pharmacology of curcumin and provides new perspectives on its therapeutic potential and limitations. Especially, the review focuses in detail on the effectiveness of curcumin and its mechanism of actions in treating neurodegenerative diseases such as Alzheimer's and Parkinson's diseases and brain malignancies.
Collapse
Affiliation(s)
- Wing-Hin Lee
- Advanced Drug Delivery Group, Faculty of Pharmacy, University of Sydney, NSW 2006, Australia
| | - Ching-Yee Loo
- Advanced Drug Delivery Group, Faculty of Pharmacy, University of Sydney, NSW 2006, Australia
| | - Mary Bebawy
- School of Pharmacy, Graduate School of Health, University of Technology Sydney PO Box 123 Broadway, NSW 2007, Australia
| | - Frederick Luk
- School of Pharmacy, Graduate School of Health, University of Technology Sydney PO Box 123 Broadway, NSW 2007, Australia
| | - Rebecca S Mason
- Physiology and Bosch Institute, University of Sydney, NSW 2006, Australia
| | - Ramin Rohanizadeh
- Advanced Drug Delivery Group, Faculty of Pharmacy, University of Sydney, NSW 2006, Australia
| |
Collapse
|
30
|
Kroker KS, Moreth J, Kussmaul L, Rast G, Rosenbrock H. Restoring long-term potentiation impaired by amyloid-beta oligomers: Comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists. Brain Res Bull 2013; 96:28-38. [DOI: 10.1016/j.brainresbull.2013.04.006] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2013] [Revised: 04/12/2013] [Accepted: 04/15/2013] [Indexed: 12/25/2022]
|
31
|
Liu J, Feng L, Ma D, Zhang M, Gu J, Wang S, Fu Q, Song Y, Lan Z, Qu R, Ma S. Neuroprotective effect of paeonol on cognition deficits of diabetic encephalopathy in streptozotocin-induced diabetic rat. Neurosci Lett 2013; 549:63-8. [PMID: 23791853 DOI: 10.1016/j.neulet.2013.06.002] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Revised: 05/15/2013] [Accepted: 06/02/2013] [Indexed: 11/29/2022]
Abstract
Diabetic encephalopathy (DE) has been characterized by the impaired cognition and the abnormalities of neurochemistry and neurostructure. The study was conducted to evaluate the neuroprotective effect of paeonol on STZ-induced DE rats. Paeonol of 25, 50, 100mg/kg (p.o.) could decrease the latency time and path length, and enhance significantly the spent time in the target quadrant and platform crossings in Morris water maze test. The treatment with paeonol could also increase significantly Na(+)-K(+)-ATP enzyme and ChAT activities, as well as decreasing significantly AchE activity in hippocampal tissue. Immunohistochemistry and TUNEL staining showed that paeonol could attenuate apoptosis of neurons and caspase 3 expression, improve two neurotrophic factors BDNF and IGF expressions, and also ameliorate Aβ deposition in the hippocampus and cerebral cortex. In conclusion, the present study demonstrated diabetic rats treated with paeonol could ameliorate the cognition deficits. These findings indicated paeonol might act as a beneficial agent for the prevention and treatment of DE.
Collapse
Affiliation(s)
- Jiping Liu
- Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, Nanjing, Jiangsu 210009, PR China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Savelieff MG, Lee S, Liu Y, Lim MH. Untangling amyloid-β, tau, and metals in Alzheimer's disease. ACS Chem Biol 2013; 8:856-65. [PMID: 23506614 DOI: 10.1021/cb400080f] [Citation(s) in RCA: 287] [Impact Index Per Article: 26.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Protein misfolding and metal ion dyshomeostasis are believed to underlie numerous neurodegenerative diseases, including Alzheimer's disease (AD). The pathological hallmark of AD is accumulation of misfolded amyloid-β (Aβ) peptides and hyperphosphorylated tau (ptau) proteins in the brain. Since AD etiology remains unclear, several hypotheses have emerged to elucidate its pathological pathways. The amyloid cascade hypothesis, a leading hypothesis for AD development, advocates Aβ as the principal culprit. Additionally, evidence suggests that tau may contribute to AD pathology. Aβ and tau have also been shown to impact each other's pathology either directly or indirectly. Furthermore, metal ion dyshomeostasis is associated with these misfolded proteins. Metal interactions with Aβ and tau/ptau also influence their aggregation properties and neurotoxicity. Herein, we present current understanding on the roles of Aβ, tau, and metal ions, placing equal emphasis on each of these proposed features, as well as their inter-relationships in AD pathogenesis.
Collapse
Affiliation(s)
- Masha G. Savelieff
- Life
Sciences Institute and ‡Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109,
United States
| | - Sanghyun Lee
- Life
Sciences Institute and ‡Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109,
United States
| | - Yuzhong Liu
- Life
Sciences Institute and ‡Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109,
United States
| | - Mi Hee Lim
- Life
Sciences Institute and ‡Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109,
United States
| |
Collapse
|
33
|
Andersson K, Pokrzywa M, Dacklin I, Lundgren E. Inhibition of TTR aggregation-induced cell death--a new role for serum amyloid P component. PLoS One 2013; 8:e55766. [PMID: 23390551 PMCID: PMC3563535 DOI: 10.1371/journal.pone.0055766] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2012] [Accepted: 01/04/2013] [Indexed: 11/18/2022] Open
Abstract
Background Serum amyloid P component (SAP) is a glycoprotein that is universally found associated with different types of amyloid deposits. It has been suggested that it stabilizes amyloid fibrils and therefore protects them from proteolytic degradation. Methodology/Principal Findings In this paper, we show that SAP binds not only to mature amyloid fibrils but also to early aggregates of amyloidogenic mutants of the plasma protein transthyretin (TTR). It does not inhibit fibril formation of TTR mutants, which spontaneously form amyloid in vitro at physiological pH. We found that SAP prevents cell death induced by mutant TTR, while several other molecules that are also known to decorate amyloid fibrils do not have such effect. Using a Drosophila model for TTR-associated amyloidosis, we found a new role for SAP as a protective factor in inhibition of TTR-induced toxicity. Overexpression of mutated TTR leads to a neurological phenotype with changes in wing posture. SAP-transgenic flies were crossed with mutated TTR-expressing flies and the results clearly confirmed a protective effect of SAP on TTR-induced phenotype, with an almost complete reduction in abnormal wing posture. Furthermore, we found in vivo that binding of SAP to mutated TTR counteracts the otherwise detrimental effects of aggregation of amyloidogenic TTR on retinal structure. Conclusions/Significance Together, these two approaches firmly establish the protective effect of SAP on TTR-induced cell death and degenerative phenotypes, and suggest a novel role for SAP through which the toxicity of early amyloidogenic aggregates is attenuated.
Collapse
Affiliation(s)
- Karin Andersson
- Department of Molecular Biology, Umeå University, Umeå, Sweden
| | - Malgorzata Pokrzywa
- Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
- * E-mail: (EL); (MP)
| | - Ingrid Dacklin
- Department of Molecular Biology, Umeå University, Umeå, Sweden
| | - Erik Lundgren
- Department of Molecular Biology, Umeå University, Umeå, Sweden
- * E-mail: (EL); (MP)
| |
Collapse
|
34
|
Abstract
With advancing age, the brain becomes increasingly susceptible to neurodegenerative diseases, most of which are characterized by the misfolding and errant aggregation of certain proteins. The induction of aggregation involves a crystallization-like seeding mechanism by which a specific protein is structurally corrupted by its misfolded conformer. The latest research indicates that, once formed, proteopathic seeds can spread from one locale to another via cellular uptake, transport, and release. Impeding this process could represent a unified therapeutic strategy for slowing the progression of a wide range of currently intractable disorders.
Collapse
Affiliation(s)
- Lary C. Walker
- From the Yerkes National Primate Research Center and Department of Neurology, Emory University, Atlanta, Georgia 30329 and
| | - Harry LeVine
- the Center on Aging, Center for Structural Biology, and Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky 40536
| |
Collapse
|
35
|
Abstract
Alzheimer's disease (AD) is the major cause of dementia. During the development of AD, neurofibrillary tangles progress in a fixed pattern, starting in the transentorhinal cortex followed by the hippocampus and cortical areas. In contrast, the deposition of β-amyloid (Aβ) plaques, which are the other histological hallmark of AD, does not follow the same strict spatiotemporal pattern, and it correlates poorly with cognitive decline. Instead, soluble Aβ oligomers have received increasing attention as probable inducers of pathogenesis. In this study, we use microinjections into electrophysiologically defined primary hippocampal rat neurons to demonstrate the direct neuron-to-neuron transfer of soluble oligomeric Aβ. Additional studies conducted in a human donor-acceptor cell model show that this Aβ transfer depends on direct cellular connections. As the transferred oligomers accumulate, acceptor cells gradually show beading of tubulin, a sign of neurite damage, and gradual endosomal leakage, a sign of cytotoxicity. These observations support that intracellular Aβ oligomers play a role in neurodegeneration, and they explain the manner in which Aβ can drive disease progression, even if the extracellular plaque load is poorly correlated with the degree of cognitive decline. Understanding this phenomenon sheds light on the pathophysiological mechanism of AD progression. Additional elucidation will help uncover the detailed mechanisms responsible for the manner in which AD progresses via anatomical connections and will facilitate the development of new strategies for stopping the progression of this incapacitating disease.
Collapse
|
36
|
Probst G, Xu YZ. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011). Expert Opin Ther Pat 2012; 22:511-40. [PMID: 22512789 DOI: 10.1517/13543776.2012.681302] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
INTRODUCTION Alzheimer's disease is a devastating neurodegenerative disorder for which no disease-modifying therapy exists. The amyloid hypothesis, which implicates Aβ as the toxin initiating a biological cascade leading to neurodegeneration, is the most prominent theory concerning the underlying cause of the disease. BACE1 is one of two aspartyl proteinases that generate Aβ, thus inhibition of BACE1 has the potential to ameliorate the progression of Alzheimer's disease by abating the production of Aβ. AREAS COVERED This review chronicles small-molecule BACE1 inhibitors as described in the patent literature between 2006 and 2011 and their potential use as disease-modifying treatments for Alzheimer's disease. Over the past half a dozen years, numerous BACE1 inhibitors have been published in the patent applications, but often these contain a paltry amount of pertinent biological data (e.g. potency, selectivity, and efficacy). Fortunately, numerous relevant publications containing important data have appeared in the journal literature during this period. The goal in this effort was to create an amalgam of the two records to add value to this review. EXPERT OPINION The pharmaceutical industry has made tremendous progress in the development of small-molecule BACE1 inhibitors that lower Aβ in the central nervous system. Assuming the amyloid hypothesis is veracious, we anticipate a disease-modifying therapy to combat Alzheimer's disease is near.
Collapse
Affiliation(s)
- Gary Probst
- Elan Pharmaceuticals, Molecular Design, 180 Oyster Point Boulevard, South San Francisco, CA 94080, USA.
| | | |
Collapse
|
37
|
Dineen TA, Weiss MM, Williamson T, Acton P, Babu-Khan S, Bartberger MD, Brown J, Chen K, Cheng Y, Citron M, Croghan MD, Dunn RT, Esmay J, Graceffa RF, Harried SS, Hickman D, Hitchcock SA, Horne DB, Huang H, Imbeah-Ampiah R, Judd T, Kaller MR, Kreiman CR, La DS, Li V, Lopez P, Louie S, Monenschein H, Nguyen TT, Pennington LD, San Miguel T, Sickmier EA, Vargas HM, Wahl RC, Wen PH, Whittington DA, Wood S, Xue Q, Yang BH, Patel VF, Zhong W. Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors. J Med Chem 2012; 55:9025-44. [DOI: 10.1021/jm300118s] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Thomas A. Dineen
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Matthew M. Weiss
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Toni Williamson
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Paul Acton
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Safura Babu-Khan
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Michael D. Bartberger
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - James Brown
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Kui Chen
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Yuan Cheng
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Martin Citron
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Michael D. Croghan
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Robert T. Dunn
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Joel Esmay
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Russell F. Graceffa
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Scott S. Harried
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Dean Hickman
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Stephen A. Hitchcock
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Daniel B. Horne
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Hongbing Huang
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Ronke Imbeah-Ampiah
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Ted Judd
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Matthew R. Kaller
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Charles R. Kreiman
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Daniel S. La
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Vivian Li
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Patricia Lopez
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Steven Louie
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Holger Monenschein
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Thomas T. Nguyen
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Lewis D. Pennington
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Tisha San Miguel
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - E. Allen Sickmier
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Hugo M. Vargas
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Robert C. Wahl
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Paul H. Wen
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Douglas A. Whittington
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Stephen Wood
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Qiufen Xue
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Bryant H. Yang
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Vinod F. Patel
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Wenge Zhong
- Chemical
Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
- Department
of Neuroscience, §Department of HTS and Molecular Pharmacology, ∥Molecular Structure, ⊥Pharmacokinetics
and Drug Metabolism, #Comparative Biology and Safety Sciences, Amgen Inc., One
Amgen Center Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|
38
|
Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci 2012; 32:2696-702. [PMID: 22357853 DOI: 10.1523/jneurosci.1676-11.2012] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Several anti-amyloid β (Aβ) antibodies are under evaluation for the treatment of Alzheimer's disease (AD). Clinical studies using the N-terminal-directed anti-Aβ antibody bapineuzumab have demonstrated reduced brain PET-Pittsburg-B signals, suggesting the reduction of Aβ plaques, and reduced levels of total and phosphorylated tau protein in the CSF of treated AD patients. Preclinical studies using 3D6 (the murine form of bapineuzumab) have demonstrated resolution of Aβ plaque and vascular burdens, neuritic dystrophy, and preservation of synaptic density in the transgenic APP mouse models. In contrast, few studies have evaluated the direct interaction of this antibody with synaptotoxic soluble Aβ species. In the current report, we demonstrated that 3D6 binds to soluble, synaptotoxic assemblies of Aβ(1-42) and prevents multiple downstream functional consequences in rat hippocampal neurons including changes in glutamate AMPA receptor trafficking, AD-type tau phosphorylation, and loss of dendritic spines. In vivo, we further demonstrated that 3D6 prevents synaptic loss and acutely reverses the behavioral deficit in the contextual fear conditioning task in transgenic mouse models of AD, two endpoints thought to be linked to synaptotoxic soluble Aβ moieties. Importantly C-terminal anti-Aβ antibodies were ineffective on these endpoints. These results, taken with prior studies, suggest that N-terminal anti-Aβ antibodies effectively interact with both soluble and insoluble forms of Aβ and therefore appear particularly well suited for testing the Aβ hypothesis of AD.
Collapse
|
39
|
Pryor NE, Moss MA, Hestekin CN. Unraveling the early events of amyloid-β protein (Aβ) aggregation: techniques for the determination of Aβ aggregate size. Int J Mol Sci 2012; 13:3038-3072. [PMID: 22489141 PMCID: PMC3317702 DOI: 10.3390/ijms13033038] [Citation(s) in RCA: 77] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2011] [Revised: 02/09/2012] [Accepted: 02/23/2012] [Indexed: 11/16/2022] Open
Abstract
The aggregation of proteins into insoluble amyloid fibrils coincides with the onset of numerous diseases. An array of techniques is available to study the different stages of the amyloid aggregation process. Recently, emphasis has been placed upon the analysis of oligomeric amyloid species, which have been hypothesized to play a key role in disease progression. This paper reviews techniques utilized to study aggregation of the amyloid-β protein (Aβ) associated with Alzheimer's disease. In particular, the review focuses on techniques that provide information about the size or quantity of oligomeric Aβ species formed during the early stages of aggregation, including native-PAGE, SDS-PAGE, Western blotting, capillary electrophoresis, mass spectrometry, fluorescence correlation spectroscopy, light scattering, size exclusion chromatography, centrifugation, enzyme-linked immunosorbent assay, and dot blotting.
Collapse
MESH Headings
- Alzheimer Disease/etiology
- Alzheimer Disease/metabolism
- Amyloid beta-Peptides/chemistry
- Amyloid beta-Peptides/metabolism
- Blotting, Western
- Chromatography, Gel
- Disease Progression
- Electrophoresis, Capillary
- Electrophoresis, Polyacrylamide Gel
- Humans
- Particle Size
- Protein Aggregates
- Protein Aggregation, Pathological
- Protein Multimerization
- Protein Structure, Quaternary
- Scattering, Radiation
- Spectrometry, Fluorescence
- Spectrometry, Mass, Electrospray Ionization
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Collapse
Affiliation(s)
- N. Elizabeth Pryor
- Ralph E. Martin Department of Chemical Engineering, 3202 Bell Engineering Center, University of Arkansas, Fayetteville, AR 72701, USA; E-Mail:
| | - Melissa A. Moss
- Department of Chemical Engineering, 2C02 Swearingen Engineering Center, University of South Carolina, Columbia, SC 29208, USA; E-Mail:
| | - Christa N. Hestekin
- Ralph E. Martin Department of Chemical Engineering, 3202 Bell Engineering Center, University of Arkansas, Fayetteville, AR 72701, USA; E-Mail:
| |
Collapse
|
40
|
Cohen SIA, Vendruscolo M, Dobson CM, Knowles TPJ. Nucleated polymerization with secondary pathways. III. Equilibrium behavior and oligomer populations. J Chem Phys 2012; 135:065107. [PMID: 21842956 DOI: 10.1063/1.3608918] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
We explore the long-time behavior and equilibrium properties of a system of linear filaments growing through nucleated polymerisation. We show that the length distribution for breakable filaments evolves through two well defined limiting cases: first, a steady state distribution determined by the balance of breakage and elongation is reached; upon monomer depletion at the end of the growth phase, an equilibrium length distribution biased towards smaller filament fragments emerges. We furthermore compute the time evolution of the concentration of small oligomeric filament fragments. For frangible filaments, oligomers are present both at early times and at equilibrium, whereas in the absence of fragmentation, oligomers are only present in significant quantities at the beginning of the polymerisation reaction. Finally, we discuss the significance of these results for the biological consequences of filamentous protein aggregation.
Collapse
Affiliation(s)
- Samuel I A Cohen
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | | | | | | |
Collapse
|
41
|
Shammas SL, Waudby CA, Wang S, Buell AK, Knowles TPJ, Ecroyd H, Welland ME, Carver JA, Dobson CM, Meehan S. Binding of the molecular chaperone αB-crystallin to Aβ amyloid fibrils inhibits fibril elongation. Biophys J 2012; 101:1681-9. [PMID: 21961594 DOI: 10.1016/j.bpj.2011.07.056] [Citation(s) in RCA: 128] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2010] [Revised: 07/20/2011] [Accepted: 07/25/2011] [Indexed: 11/24/2022] Open
Abstract
The molecular chaperone αB-crystallin is a small heat-shock protein that is upregulated in response to a multitude of stress stimuli, and is found colocalized with Aβ amyloid fibrils in the extracellular plaques that are characteristic of Alzheimer's disease. We investigated whether this archetypical small heat-shock protein has the ability to interact with Aβ fibrils in vitro. We find that αB-crystallin binds to wild-type Aβ(42) fibrils with micromolar affinity, and also binds to fibrils formed from the E22G Arctic mutation of Aβ(42). Immunoelectron microscopy confirms that binding occurs along the entire length and ends of the fibrils. Investigations into the effect of αB-crystallin on the seeded growth of Aβ fibrils, both in solution and on the surface of a quartz crystal microbalance biosensor, reveal that the binding of αB-crystallin to seed fibrils strongly inhibits their elongation. Because the lag phase in sigmoidal fibril assembly kinetics is dominated by elongation and fragmentation rates, the chaperone mechanism identified here represents a highly effective means to inhibit fibril proliferation. Together with previous observations of αB-crystallin interaction with α-synuclein and insulin fibrils, the results suggest that this mechanism is a generic means of providing molecular chaperone protection against amyloid fibril formation.
Collapse
Affiliation(s)
- Sarah L Shammas
- Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Papadopoulos V, Lecanu L. Caprospinol: discovery of a steroid drug candidate to treat Alzheimer's disease based on 22R-hydroxycholesterol structure and properties. J Neuroendocrinol 2012; 24:93-101. [PMID: 21623958 DOI: 10.1111/j.1365-2826.2011.02167.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The overall ability of the brain to synthesise neuroactive steroids led us to the identification of compounds that would reproduce aspects of neurosteroid pharmacology. The rate-determining step in neurosteroid biosynthesis is the import of the substrate cholesterol into the mitochondria, where it is metabolised into pregnenolone via the intermediate 22R-hydroxycholesterol. The levels of translocator protein 18-kDa, mediating the import of cholesterol into mitochondria, correlated with increased pregnenolone formation and reduced levels of 22R-hydroxycholesterol in biopsies from Alzheimer's disease (AD), but not age-matched control, brains. 22R-hydroxycholesterol was shown to protect against β-amyloid (Aβ(42) )-induced neurotoxicity. In search of 22R-hydroxycholesterol stable analogues, we identified the naturally occurring heterospirostenol, (22R,25R)-20α-spirost-5-en-3β-yl hexanoate (caprospinol) and derivatives that protect neuronal cells against Aβ(1-42) neurotoxicity. The neuroprotective effect of caprospinol is the result of a combination of overlapping properties, including: (i) the ability to bind to Aβ(42) and reduce plaque formation in the brain in vivo; (ii) interaction with components of the mitochondria respiratory chain resulting in an anti-uncoupling effect; (iii) the capacity to scavenge Aβ(42) monomers present in mitochondria; and (iv) the property of being a sigma-1 receptor ligand. In vivo, caprospinol crosses the blood-brain barrier, accumulates in the brain, and restores cognitive impairment in a pharmacological rat model of AD. Caprospinol is stable, does not bind to known steroid receptors, is devoid of mutagenic and genotoxic properties, and is devoid of acute toxicity in rodents. The pharmacokinetics and pharmacodynamics of caprospinol were studied, and long-term toxicity studies are under investigation, aiming to develop this compound as a disease-modifying drug for the treatment of AD.
Collapse
Affiliation(s)
- V Papadopoulos
- The Research Institute of the McGill University Health Centre and Department of Medicine, McGill University, Montreal, Canada.
| | | |
Collapse
|
43
|
Frydman-Marom A, Convertino M, Pellarin R, Lampel A, Shaltiel-Karyo R, Segal D, Caflisch A, Shalev DE, Gazit E. Structural basis for inhibiting β-amyloid oligomerization by a non-coded β-breaker-substituted endomorphin analogue. ACS Chem Biol 2011; 6:1265-76. [PMID: 21892833 DOI: 10.1021/cb200103h] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The distribution of endomorphins (EM) 1 and 2 in the human brain inversely correlates with cerebral neurodegeneration in Alzheimer's disease (AD), implying a protective role. These endogenous opioid peptides incorporate aromatic residues and a β-breaker motif, as seen in several optimized inhibitors of Aβ aggregation. The activity of native endomorphins was studied, as well as the rationally designed analogue Aib-1, which includes a remarkably efficient β-breaker, α-aminoisobutyric acid (Aib). In vitro and GFP fusion protein assays showed that Aib-1 interacted with Aβ and markedly inhibited the formation of toxic oligomer and fibril growth. Moreover, Aib-1 prevented the toxicity of Aβ toward neuronal PC12 cells and markedly rectified reduced longevity of an AD fly model. Atomistic simulations and NMR-derived solution structures revealed that Aib-1 significantly reduced the propensity of Aβ to aggregate due to multimode interactions including aromatic, hydrophobic, and polar contacts. We suggest that hindering the self-assembly process by interfering with the aromatic core of amyloidogenic peptides may pave the way toward developing therapeutic agents to treat amyloid-associated diseases.
Collapse
Affiliation(s)
- Anat Frydman-Marom
- Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Tel-Aviv 69978, Israel
| | - Marino Convertino
- Department of Biochemistry, University of Zurich, CH-8057 Zurich, Switzerland
| | - Riccardo Pellarin
- Department of Biochemistry, University of Zurich, CH-8057 Zurich, Switzerland
| | - Ayala Lampel
- Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Tel-Aviv 69978, Israel
| | - Ronit Shaltiel-Karyo
- Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Tel-Aviv 69978, Israel
| | - Daniel Segal
- Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Tel-Aviv 69978, Israel
| | - Amedeo Caflisch
- Department of Biochemistry, University of Zurich, CH-8057 Zurich, Switzerland
| | - Deborah E. Shalev
- Wolfson Centre for Applied Structural Biology, Hebrew University of Jerusalem, Safra Campus, Givat Ram, Jerusalem 91904, Israel
| | - Ehud Gazit
- Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Tel-Aviv 69978, Israel
| |
Collapse
|
44
|
Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011; 6:e21954. [PMID: 21799757 PMCID: PMC3142110 DOI: 10.1371/journal.pone.0021954] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2011] [Accepted: 06/15/2011] [Indexed: 01/20/2023] Open
Abstract
Overproduction of amyloid-β (Aβ) protein in the brain has been hypothesized as the primary toxic insult that, via numerous mechanisms, produces cognitive deficits in Alzheimer's disease (AD). Cholinesterase inhibition is a primary strategy for treatment of AD, and specific compounds of this class have previously been demonstrated to influence Aβ precursor protein (APP) processing and Aβ production. However, little information is available on the effects of rivastigmine, a dual acetylcholinesterase and butyrylcholinesterase inhibitor, on APP processing. As this drug is currently used to treat AD, characterization of its various activities is important to optimize its clinical utility. We have previously shown that rivastigmine can preserve or enhance neuronal and synaptic terminal markers in degenerating primary embryonic cerebrocortical cultures. Given previous reports on the effects of APP and Aβ on synapses, regulation of APP processing represents a plausible mechanism for the synaptic effects of rivastigmine. To test this hypothesis, we treated degenerating primary cultures with rivastigmine and measured secreted APP (sAPP) and Aβ. Rivastigmine treatment increased metabolic activity in these cultured cells, and elevated APP secretion. Analysis of the two major forms of APP secreted by these cultures, attributed to neurons or glia based on molecular weight showed that rivastigmine treatment significantly increased neuronal relative to glial secreted APP. Furthermore, rivastigmine treatment increased α-secretase cleaved sAPPα and decreased Aβ secretion, suggesting a therapeutic mechanism wherein rivastigmine alters the relative activities of the secretase pathways. Assessment of sAPP levels in rodent CSF following once daily rivastigmine administration for 21 days confirmed that elevated levels of APP in cell culture translated in vivo. Taken together, rivastigmine treatment enhances neuronal sAPP and shifts APP processing toward the α-secretase pathway in degenerating neuronal cultures, which mirrors the trend of synaptic proteins, and metabolic activity.
Collapse
Affiliation(s)
- Jason A. Bailey
- Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
| | - Balmiki Ray
- Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
| | - Nigel H. Greig
- Laboratory of Neuroscience, Intramural Research Program, National Institute of Aging, National Institutes of Health, Baltimore Maryland, United States of America
| | - Debomoy K. Lahiri
- Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
- Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
- * E-mail:
| |
Collapse
|
45
|
Rueeger H, Rondeau JM, McCarthy C, Möbitz H, Tintelnot-Blomley M, Neumann U, Desrayaud S. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors. Bioorg Med Chem Lett 2011; 21:1942-7. [DOI: 10.1016/j.bmcl.2011.02.038] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2010] [Revised: 02/09/2011] [Accepted: 02/10/2011] [Indexed: 01/16/2023]
|
46
|
Abstract
Current interest in amyloid fibrils stems from their involvement in neurodegenerative and other diseases and from their role as an alternative structural state for many peptides and proteins. Solid-state nuclear magnetic resonance (NMR) methods have the unique capability of providing detailed structural constraints for amyloid fibrils, sufficient for the development of full molecular models. In this article, recent progress in the application of solid-state NMR to fibrils associated with Alzheimer's disease, prion fibrils, and related systems is reviewed, along with relevant developments in solid-state NMR techniques and technology.
Collapse
Affiliation(s)
- Robert Tycko
- Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0520, USA.
| |
Collapse
|
47
|
Pokrzywa M, Dacklin I, Vestling M, Hultmark D, Lundgren E, Cantera R. Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis. PLoS One 2010; 5:e14343. [PMID: 21179560 PMCID: PMC3002944 DOI: 10.1371/journal.pone.0014343] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2010] [Accepted: 11/11/2010] [Indexed: 01/26/2023] Open
Abstract
Background A functional link has been established between the severe neurodegenerative disorder Familial amyloidotic polyneuropathy and the enhanced propensity of the plasma protein transthyretin (TTR) to form aggregates in patients with single point mutations in the TTR gene. Previous work has led to the establishment of an experimental model based on transgenic expression of normal or mutant forms of human TTR in Drosophila flies. Remarkably, the severity of the phenotype was greater in flies that expressed a single copy than with two copies of the mutated gene. Methodology/Principal Findings In this study, we analyze the distribution of normal and mutant TTR in transgenic flies, and the ultrastructure of TTR-positive tissues to clarify if aggregates and/or amyloid filaments are formed. We report the formation of intracellular aggregates of 20 nm spherules and amyloid filaments in thoracic adipose tissue and in brain glia, two tissues that do not express the transgene. The formation of aggregates of nanospherules increased with age and was more considerable in flies with two copies of mutated TTR. Treatment of human neuronal cells with protein extracts prepared from TTR flies of different age showed that the extracts from older flies were less toxic than those from younger flies. Conclusions/Significance These findings suggest that the uptake of TTR from the circulation and its subsequent segregation into cytoplasmic quasi-crystalline arrays of nanospherules is part of a mechanism that neutralizes the toxic effect of TTR.
Collapse
|
48
|
Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 2010; 6:551-9. [PMID: 20842183 DOI: 10.1038/nrneurol.2010.130] [Citation(s) in RCA: 312] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Diabetes and Alzheimer disease (AD)-two age-related diseases-are both increasing in prevalence, and numerous studies have demonstrated that patients with diabetes have an increased risk of developing AD compared with healthy individuals. The underlying biological mechanisms that link the development of diabetes with AD are not fully understood. Abnormal protein processing, abnormalities in insulin signaling, dysregulated glucose metabolism, oxidative stress, the formation of advanced glycation end products, and the activation of inflammatory pathways are features common to both diseases. Hypercholesterolemia is another factor that has received attention, owing to its potential association with diabetes and AD. This Review summarizes the mechanistic pathways that might link diabetes and AD. An understanding of this complex interaction is necessary for the development of novel drug therapies and lifestyle guidelines aimed at the treatment and/or prevention of these diseases.
Collapse
|
49
|
Krafft GA, Klein WL. ADDLs and the signaling web that leads to Alzheimer’s disease. Neuropharmacology 2010; 59:230-42. [DOI: 10.1016/j.neuropharm.2010.07.012] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2010] [Accepted: 07/13/2010] [Indexed: 12/29/2022]
|
50
|
Truong AP, Tóth G, Probst GD, Sealy JM, Bowers S, Wone DWG, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM. Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett 2010; 20:6231-6. [PMID: 20833041 DOI: 10.1016/j.bmcl.2010.08.102] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2010] [Revised: 08/18/2010] [Accepted: 08/19/2010] [Indexed: 12/17/2022]
Abstract
In this Letter, we describe our efforts to design HEA BACE-1 inhibitors that are highly permeable coupled with negligible levels of permeability-glycoprotein activity. These efforts culminate in producing 16 which lowers Αβ by 28% and 32% in the cortex and CSF, respectively, in the preclinical wild type Hartley guinea pig animal model when dosed orally at 30mpk BID for 2.5days.
Collapse
Affiliation(s)
- Anh P Truong
- Department of Medicinal Chemistry, Elan Pharmaceuticals, 180 Oyster Point Boulevard, South San Francisco, CA 94080, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|